{"name":"Gustave Roussy, Cancer Campus, Grand Paris","slug":"gustave-roussy-cancer-campus-grand-paris","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":16,"colorKey":"oncology","drugs":[{"name":"DS-1062a","genericName":"DS-1062a","slug":"ds-1062a","indication":"Advanced or metastatic non-small cell lung cancer","status":"phase_3"},{"name":"Etoposide, carboplatin, melphalan, cisplatin, thiotepa","genericName":"Etoposide, carboplatin, melphalan, cisplatin, thiotepa","slug":"etoposide-carboplatin-melphalan-cisplatin-thiotepa","indication":"Small cell lung cancer","status":"phase_2"},{"name":"doxorubicin, ifosfamide, cisplatin","genericName":"doxorubicin, ifosfamide, cisplatin","slug":"doxorubicin-ifosfamide-cisplatin","indication":"Metastatic urothelial carcinoma","status":"phase_3"},{"name":"ASP3082","genericName":"ASP3082","slug":"asp3082","indication":"Solid tumors","status":"phase_2"},{"name":"Anti-PD-L1 antibody atezolizumab","genericName":"Anti-PD-L1 antibody atezolizumab","slug":"anti-pd-l1-antibody-atezolizumab","indication":"Non-small cell lung cancer","status":"phase_2"},{"name":"Doxorubicin, Methotrexate","genericName":"Doxorubicin, Methotrexate","slug":"doxorubicin-methotrexate","indication":"Breast cancer (likely primary indication given phase 3 status)","status":"phase_3"},{"name":"Etoposide, Ifosfamide, Methotrexate","genericName":"Etoposide, Ifosfamide, Methotrexate","slug":"etoposide-ifosfamide-methotrexate","indication":"Pediatric and adolescent cancers (lymphomas, sarcomas, and other solid tumors)","status":"phase_3"},{"name":"Genomic driven chemotherapy","genericName":"Genomic driven chemotherapy","slug":"genomic-driven-chemotherapy","indication":"Solid tumors with genomic profiling-guided chemotherapy selection","status":"phase_3"},{"name":"I131","genericName":"I131","slug":"i131","indication":"Differentiated thyroid cancer (papillary and follicular) with radioactive iodine-avid metastases","status":"phase_3"},{"name":"Isolated pelvis perfusion","genericName":"Isolated pelvis perfusion","slug":"isolated-pelvis-perfusion","indication":"Advanced pelvic malignancies (sarcoma, gynecologic cancers, colorectal cancer)","status":"phase_3"},{"name":"LMB B","genericName":"LMB B","slug":"lmb-b","indication":"Cutaneous T-cell lymphoma (mycosis fungoides)","status":"phase_3"},{"name":"LMB C","genericName":"LMB C","slug":"lmb-c","indication":"Cutaneous T-cell lymphoma (mycosis fungoides)","status":"phase_3"},{"name":"half cyclophosphamide","genericName":"half cyclophosphamide","slug":"half-cyclophosphamide","indication":"Cancer conditioning in hematopoietic stem cell transplantation","status":"phase_3"},{"name":"mini CYVE, without 3 maintenance courses","genericName":"mini CYVE, without 3 maintenance courses","slug":"mini-cyve-without-3-maintenance-courses","indication":"Relapsed or refractory multiple myeloma","status":"phase_3"},{"name":"rhTSH","genericName":"rhTSH","slug":"rhtsh","indication":"Thyroid cancer (radioactive iodine ablation adjunct)","status":"marketed"},{"name":"rhTSH stimulation","genericName":"rhTSH stimulation","slug":"rhtsh-stimulation","indication":"Differentiated thyroid cancer requiring radioactive iodine therapy","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"immunology","drugs":[{"name":"Thromboprophylaxis","genericName":"Thromboprophylaxis","slug":"thromboprophylaxis","indication":"Other","status":"phase_3"},{"name":"BEP Protocol","genericName":"BEP Protocol","slug":"bep-protocol","indication":"Other","status":"phase_1"},{"name":"Fadraciclib","genericName":"Fadraciclib","slug":"fadraciclib","indication":"Other","status":"phase_1"},{"name":"HPVDC injection level dose 1","genericName":"HPVDC injection level dose 1","slug":"hpvdc-injection-level-dose-1","indication":"Other","status":"phase_1"},{"name":"Peposertib","genericName":"Peposertib","slug":"peposertib","indication":"Other","status":"phase_1"},{"name":"without COPADM3","genericName":"without COPADM3","slug":"without-copadm3","indication":"Other","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Vistide","genericName":"Vistide","slug":"vistide","indication":"Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients","status":"marketed"}]}],"pipeline":[{"name":"DS-1062a","genericName":"DS-1062a","slug":"ds-1062a","phase":"phase_3","mechanism":"DS-1062a is an antibody-drug conjugate that targets TROP-2 on cancer cells and delivers a topoisomerase I inhibitor payload to induce cell death.","indications":["Advanced or metastatic non-small cell lung cancer","Advanced gastric or gastroesophageal junction cancer"],"catalyst":""},{"name":"Etoposide, carboplatin, melphalan, cisplatin, thiotepa","genericName":"Etoposide, carboplatin, melphalan, cisplatin, thiotepa","slug":"etoposide-carboplatin-melphalan-cisplatin-thiotepa","phase":"phase_2","mechanism":"Etoposide, carboplatin, melphalan, cisplatin, and thiotepa are chemotherapeutic agents that work by interfering with DNA replication and cell division, ultimately leading to cell death.","indications":["Small cell lung cancer","Non-small cell lung cancer","Ovarian cancer","Testicular cancer","Breast cancer"],"catalyst":""},{"name":"Thromboprophylaxis","genericName":"Thromboprophylaxis","slug":"thromboprophylaxis","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"doxorubicin, ifosfamide, cisplatin","genericName":"doxorubicin, ifosfamide, cisplatin","slug":"doxorubicin-ifosfamide-cisplatin","phase":"phase_3","mechanism":"Doxorubicin, ifosfamide, and cisplatin work by interfering with DNA replication and function, leading to cell death in rapidly dividing cancer cells.","indications":["Metastatic urothelial carcinoma","Metastatic non-small cell lung cancer","Soft tissue sarcoma"],"catalyst":""},{"name":"ASP3082","genericName":"ASP3082","slug":"asp3082","phase":"phase_2","mechanism":"ASP3082 is an investigational drug with unknown mechanism of action.","indications":["Solid tumors"],"catalyst":""},{"name":"Anti-PD-L1 antibody atezolizumab","genericName":"Anti-PD-L1 antibody atezolizumab","slug":"anti-pd-l1-antibody-atezolizumab","phase":"phase_2","mechanism":"Atezolizumab blocks the PD-L1 checkpoint protein on tumor cells, preventing it from suppressing anti-tumor immune responses and allowing T cells to attack cancer.","indications":["Non-small cell lung cancer","Urothelial carcinoma","Triple-negative breast cancer","Other solid tumors (phase 2 evaluation)"],"catalyst":""},{"name":"BEP Protocol","genericName":"BEP Protocol","slug":"bep-protocol","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Doxorubicin, Methotrexate","genericName":"Doxorubicin, Methotrexate","slug":"doxorubicin-methotrexate","phase":"phase_3","mechanism":"This combination uses doxorubicin to intercalate DNA and inhibit topoisomerase II, while methotrexate inhibits dihydrofolate reductase to disrupt nucleotide synthesis, together producing synergistic cytotoxic effects against cancer cells.","indications":["Breast cancer (likely primary indication given phase 3 status)","Other solid tumors or hematologic malignancies (specific indication not provided)"],"catalyst":""},{"name":"Etoposide, Ifosfamide, Methotrexate","genericName":"Etoposide, Ifosfamide, Methotrexate","slug":"etoposide-ifosfamide-methotrexate","phase":"phase_3","mechanism":"This is a combination chemotherapy regimen that kills cancer cells by damaging DNA and preventing cell division through multiple mechanisms.","indications":["Pediatric and adolescent cancers (lymphomas, sarcomas, and other solid tumors)","High-risk or relapsed/refractory malignancies"],"catalyst":""},{"name":"Fadraciclib","genericName":"Fadraciclib","slug":"fadraciclib","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Genomic driven chemotherapy","genericName":"Genomic driven chemotherapy","slug":"genomic-driven-chemotherapy","phase":"phase_3","mechanism":"Genomic-driven chemotherapy selects and administers chemotherapy agents based on individual tumor genomic profiling to optimize treatment efficacy and reduce toxicity.","indications":["Solid tumors with genomic profiling-guided chemotherapy selection"],"catalyst":""},{"name":"HPVDC injection level dose 1","genericName":"HPVDC injection level dose 1","slug":"hpvdc-injection-level-dose-1","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"I131","genericName":"I131","slug":"i131","phase":"phase_3","mechanism":"Iodine-131 is a radioactive isotope that emits beta particles to destroy thyroid cancer cells and other iodine-avid malignancies.","indications":["Differentiated thyroid cancer (papillary and follicular) with radioactive iodine-avid metastases","Thyroid cancer recurrence and metastatic disease"],"catalyst":""},{"name":"Isolated pelvis perfusion","genericName":"Isolated pelvis perfusion","slug":"isolated-pelvis-perfusion","phase":"phase_3","mechanism":"Isolated pelvic perfusion delivers high-dose chemotherapy directly to pelvic tumors while minimizing systemic exposure through regional vascular isolation.","indications":["Advanced pelvic malignancies (sarcoma, gynecologic cancers, colorectal cancer)","Locally advanced or unresectable pelvic tumors"],"catalyst":""},{"name":"LMB B","genericName":"LMB B","slug":"lmb-b","phase":"phase_3","mechanism":"LMB-B is an immunotoxin that targets CD25-expressing cells by delivering a toxin payload to eliminate malignant T cells.","indications":["Cutaneous T-cell lymphoma (mycosis fungoides)","Peripheral T-cell lymphoma"],"catalyst":""},{"name":"LMB C","genericName":"LMB C","slug":"lmb-c","phase":"phase_3","mechanism":"LMB-C is an immunotoxin that targets CD25-expressing cells by delivering a toxin payload to eliminate malignant T cells.","indications":["Cutaneous T-cell lymphoma (mycosis fungoides)","Peripheral T-cell lymphoma"],"catalyst":""},{"name":"Peposertib","genericName":"Peposertib","slug":"peposertib","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Vistide","genericName":"Vistide","slug":"vistide","phase":"marketed","mechanism":"DNA polymerase catalytic subunit","indications":["Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients","CMV Retinitis in AIDS Patients"],"catalyst":""},{"name":"half cyclophosphamide","genericName":"half cyclophosphamide","slug":"half-cyclophosphamide","phase":"phase_3","mechanism":"Half-dose cyclophosphamide is a reduced-intensity alkylating agent that cross-links DNA to kill rapidly dividing cells, particularly in cancer and autoimmune contexts.","indications":["Cancer conditioning in hematopoietic stem cell transplantation","Autoimmune diseases (as part of reduced-intensity conditioning regimens)"],"catalyst":""},{"name":"mini CYVE, without 3 maintenance courses","genericName":"mini CYVE, without 3 maintenance courses","slug":"mini-cyve-without-3-maintenance-courses","phase":"phase_3","mechanism":"mini CYVE targets the CD47/SIRPα axis to promote phagocytosis of cancer cells.","indications":["Relapsed or refractory multiple myeloma"],"catalyst":""},{"name":"rhTSH","genericName":"rhTSH","slug":"rhtsh","phase":"marketed","mechanism":"rhTSH (recombinant human thyroid-stimulating hormone) stimulates the thyroid gland to produce and release thyroid hormones.","indications":["Thyroid cancer (radioactive iodine ablation adjunct)","Hypothyroidism (thyroid hormone stimulation)"],"catalyst":""},{"name":"rhTSH stimulation","genericName":"rhTSH stimulation","slug":"rhtsh-stimulation","phase":"phase_3","mechanism":"Recombinant human thyroid-stimulating hormone (rhTSH) stimulates thyroid hormone production and uptake to enhance radioactive iodine accumulation in thyroid cancer cells.","indications":["Differentiated thyroid cancer requiring radioactive iodine therapy","Thyroid cancer with distant metastases"],"catalyst":""},{"name":"without COPADM3","genericName":"without COPADM3","slug":"without-copadm3","phase":"phase_3","mechanism":"This drug targets the PD-1 receptor to inhibit cancer cell growth.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxOQl9Kd0NQMjdyU2dmLVI1blBES0hNWEJPTEk3S2xMR2FrSkF6NWFkYUIzUG5pbXFkcm4wLVhOQVRNRE93VWVzQnM4WEV3U0sxVnhKX1J1dS16VDI1S1RKUWVTZURMWFBXRUFaQXFGNkZGR0N5X1VmT3R6ZnA4a3NhYWFybFF5RGZGUzJMNFl3WFY1UzVFdVlQYVdLeGE3VFBRdU5TcWcxOUprMG42NnNyTEVGRDlIN1ZXUDg1MG1HTVVUdWdHVHdVTmlmREN5UDN6TXd2U3pwZnNCT3ZHSjA3X1ZlVnAyd2hmZldSbWo0TF9BbUdpVDIw?oc=5","date":"2025-07-10","type":"pipeline","source":"prnewswire.com","summary":"Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers - prnewswire.com","headline":"Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOR2VfVjZQR0NaWDcxOTN6WjBpZ0tZUVl6bnk2WkZoay1temhwV1J5REpVUTJNZjlHTXU5cnEtTFdDaFg1LUFJMG92Rzh0NklnaDAtR3FvNWs5X3lYM3BDYmZ3NHFzbjQ2WDNZWk5MWU55RTFyWkd0dkFtNzNXektNRnVQWVFJYmwwX2drWXhqZE9YLTNCSGc0VGpXNDlZUHZESW1BNXRwamFRaVdHLWJLcUNXWW01TmE0dnlUNkx3VQ?oc=5","date":"2025-04-02","type":"pipeline","source":"gustaveroussy.fr","summary":"The President of the French Republic lays the foundation stone for Gustave Roussy’s new research building - gustaveroussy.fr","headline":"The President of the French Republic lays the foundation stone for Gustave Roussy’s new research building","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOeWdPbS11aExBRTIza1ZlZ1lrLTNlQzdaNE04eFJKV3RRN1QwQ2gwUmxmYWJTMkJ0MUxmWmV1c1VTU0t1LUhRMllGdjFDU3BSWWFJeDI5U1ZQMVlBMlM1RThLbTVqTkJxOXgyTFVqQkJRZjZqRzVtQVAyaHdicUZNaGt3c1hHS0Q5b1U3dWM4bTVlWWoyZ1NnX1NEeUNGV296c3gtRGln?oc=5","date":"2024-09-18","type":"pipeline","source":"Pharmaceutical Executive","summary":"Keytruda Demonstrates Superior Overall Survival vs. Yervoy in Advanced Melanoma - Pharmaceutical Executive","headline":"Keytruda Demonstrates Superior Overall Survival vs. Yervoy in Advanced Melanoma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxOaWlyb2VjeW9pckRkSFJicU9OckdWQjV2U3JXcDRaemlEdlZDakhlMHlqREw2dTB0QXZoLXZkM3l5dVc5RTZvZ1c1amRucDh5bTg5eVlFeEFjX3RqVTZGT3o2RDY2OWRuSUI2SlE1eU9UaUtUem9yQmU0dmhqUTQxTXpMMkhBVHJPWGFLNE5BVHo4eGdzcEhOTDVkcU5EU0V0Z2plc0oydjJ0TE8tS3l5bnkxMEphbnlXZzB4TndYNWRFNjA?oc=5","date":"2024-02-27","type":"pipeline","source":"gustaveroussy.fr","summary":"Dana-Farber and Gustave Roussy to hold third Transatlantic Exchange: Annual scientific conference dedicated to advancing Oncology research and practice - gustaveroussy.fr","headline":"Dana-Farber and Gustave Roussy to hold third Transatlantic Exchange: Annual scientific conference dedicated to advancing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE1TN0ZoZWZHa01ZWkRvNTcxcGRzaFpwYXRQSWxjVHlqSUFUTEgzUkViLUFxa1ZVMkZVdE9MYkctMm9YTHVBTF9rVGhjSHBCbWlkQlFJMlB5N1pQV194aUcwcktqYnJfYUNzNFM3MXdOS0plR0RfZWdudl93?oc=5","date":"2023-01-27","type":"trial","source":"labiotech.eu","summary":"Onxeo to study prostate cancer drug - labiotech.eu","headline":"Onxeo to study prostate cancer drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9FSWJiUDRHbmtzNTg3dVJIMjZUMlF1M0Z0VnlRdlRTRlYtNTN4TDA1YVI4N2hvZWR6RHhmb1N3MEtkaDJ1d1J1bUNKMktpMlV5YUt0T2hQN2xwWENfeGNHd3NNVllQLVpwajlEdkhR?oc=5","date":"2022-03-08","type":"pipeline","source":"gustaveroussy.fr","summary":"Strategic Plan 2030 : interview - gustaveroussy.fr","headline":"Strategic Plan 2030 : interview","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTFBRcVdHQ1BiUE0ya3hoemtCQm1vU2ZHMy1vOTl6RDNkZVJER3p6M29ySkNBWVVVWUxWZUlxM0FFaU5FWTNnUENlOUp0OHk3TTlYZmFjQm9uUTY5WmJsZU5WMm9rcDBfX3pvU0Zj?oc=5","date":"2021-08-31","type":"pipeline","source":"Savills","summary":"European life sciences – emerging hotspots - Savills","headline":"European life sciences – emerging hotspots","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQeVF3Rl9EOE9lTDFTcV9sRWVtSWFhZUk4ZHhEb3BqVFpIRmZUbVRoV09zVXdFQjl1NXFoc3huSzdDUDh3NG1RNW1DbkVxQ1Nhbm5zaWl4S19TVDV3TWhYbzNIQ203c3hmQWJwdnpMYm93LUEwZXRudDJrb2gxSTJtb21tNElsQTExY1BRN25pNVNxN2UyZkNTaEl6b05hMTExMERZUmZKX2h1LXNnQ1R3OG10ZjZyazBo?oc=5","date":"2021-06-16","type":"patent","source":"gustaveroussy.fr","summary":"ORPHELIA Pharma and Gustave Roussy announce issuance of European Patent covering Kimozo - gustaveroussy.fr","headline":"ORPHELIA Pharma and Gustave Roussy announce issuance of European Patent covering Kimozo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQaW9mX0t3TDNaSU9oR2hrQTJwUUlSV3o5N3FoTlB3LWFjcjdMRHZ4S1ZyWDBfQWhKQmc4N2xiaDBKTUV0RmlqWEx6YmxraEtNMGllbENHeENjT01Zak9sQnd3Mjg5dF9tcWEwZFBiaFU2YUk2a0xBYUZTYlk2bDVSODVvYmVCU3NsVllxQzRRZ3B1SlliOE5qaTFYOEVXZw?oc=5","date":"2019-04-01","type":"deal","source":"Contract Pharma","summary":"XenTech SAS Partners with Gustave Roussy for Cancer - Contract Pharma","headline":"XenTech SAS Partners with Gustave Roussy for Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPU203OUtHUUtRZEVBR201MERvZTlLajI2dWFlQUhBajlvVkxMNFZRZE9QREhVYTVuWVRLMHYwSGRZUGxrck1yRFdzNXVENy0wSlRlTDFWTjlvLTJsOUJfaVlrU3JsRnRUR1EtRFBtby1uRHZSMlBFN1Q2bzFnRHItTzZENlQ3RzQ4SWJ4alN3dUY?oc=5","date":"2018-04-16","type":"pipeline","source":"Medical Xpress","summary":"Adjuvant pembrolizumab beneficial in stage III melanoma - Medical Xpress","headline":"Adjuvant pembrolizumab beneficial in stage III melanoma","sentiment":"neutral"}],"patents":[],"drugCount":23,"phaseCounts":{"phase_3":14,"phase_2":3,"phase_1":4,"marketed":2},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}